在异基因干细胞移植前对急性髓系白血病患者进行微小残留病定量：如何划定界限？ - Suppr

Quantifying MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?

作者信息

Schwind Sebastian, Bischof Lara, Bill Marius, Grimm Juliane, Ussmann Jule, Backhaus Donata, Brauer Dominic, Thanh Tung Pham, Merz Maximilian, Franke Georg-Nikolaus, Metzeler Klaus H, Vucinic Vladan, Herling Marco, Platzbecker Uwe, Jentzsch Madlen

机构信息

Medical Clinic and Policlinic 1, Hematology, Cellular Therapy, Hemostaseology, and Infectious Diseases Leipzig University Hospital Leipzig Germany.

出版信息

Hemasphere. 2024 Mar 18;8(3):e55. doi: 10.1002/hem3.55. eCollection 2024 Mar.

DOI:10.1002/hem3.55

PMID:38501048

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10946283/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3a17/10946283/0cae4b4bdd64/HEM3-8-e55-g001.jpg

相似文献

Quantifying MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?在异基因干细胞移植前对急性髓系白血病患者进行微小残留病定量：如何划定界限？

Hemasphere. 2024 Mar 18;8(3):e55. doi: 10.1002/hem3.55. eCollection 2024 Mar.

The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.无 FLT3-ITD、NPM1 和双等位 CEBPA 突变的中危急性髓系白血病微小残留病检测对预后和缓解后治疗选择的影响。

Hematology. 2021 Dec;26(1):179-185. doi: 10.1080/16078454.2021.1880753.

Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.移植前NPM1突变的定量测定显著预测完全缓解的核型正常AML患者异基因造血干细胞移植的结局。

Anticancer Res. 2016 Oct;36(10):5487-5498. doi: 10.21873/anticanres.11130.

Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.异基因造血细胞移植后进行深度 NPM1 测序可改善 NPM1 突变型 AML 成人患者的风险评估。

Biol Blood Marrow Transplant. 2018 Aug;24(8):1615-1620. doi: 10.1016/j.bbmt.2018.04.017. Epub 2018 Apr 21.

Minimal/Measurable Residual Disease Monitoring in -Mutated Acute Myeloid Leukemia: A Clinical Viewpoint and Perspectives.伴有突变的急性髓系白血病中的微小残留病监测：临床观点和展望。

Int J Mol Sci. 2018 Nov 6;19(11):3492. doi: 10.3390/ijms19113492.

NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia.基于 NPM1 突变的缓解后两疗程治疗后微小残留病评估是急性髓系白血病预后的有价值的临床预测指标。

Int J Hematol. 2022 Aug;116(2):199-214. doi: 10.1007/s12185-022-03328-6. Epub 2022 Apr 4.

Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.移植前NPM1微小残留病水平可预测急性髓系白血病患者异基因造血干细胞移植后的预后。

Blood Cancer J. 2016 Jul 29;6(7):e449. doi: 10.1038/bcj.2016.46.

Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission.移植后第 +100 天微小残留病灶检测而非嵌合状态预测完全缓解后接受异基因造血干细胞移植的中危急性髓系白血病患者的复发。

Transplant Cell Ther. 2022 Jul;28(7):374.e1-374.e9. doi: 10.1016/j.jtct.2022.04.009. Epub 2022 Apr 13.

Allogeneic stem-cell transplantation in patients with NPM1-mutated acute myeloid leukemia: results from a prospective donor versus no-donor analysis of patients after upfront HLA typing within the SAL-AML 2003 trial.NPM1 突变型急性髓系白血病患者的异基因造血干细胞移植：来自 SAL-AML 2003 试验中前瞻性 HLA 配型后供者与无供者分析的结果。

J Clin Oncol. 2015 Feb 10;33(5):403-10. doi: 10.1200/JCO.2013.54.4973. Epub 2014 Dec 29.

Acute myeloid leukemia patient with and double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis.伴有和双突变的急性髓系白血病患者应在完全缓解期1（CR1）接受异基因造血干细胞移植，以获得更好的预后。（注：原文中“and double mutation”处有信息缺失）

Cancer Manag Res. 2019 May 8;11:4129-4142. doi: 10.2147/CMAR.S194523. eCollection 2019.

引用本文的文献

Pretransplant MRD does not seem to affect survival in NPM1-mutated AML undergoing allogeneic stem cell transplantation.移植前微小残留病似乎并不影响接受异基因干细胞移植的NPM1突变型急性髓系白血病患者的生存率。

Blood Adv. 2025 Apr 8;9(7):1630-1641. doi: 10.1182/bloodadvances.2024014767.

Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML.基于基因组DNA的新一代测序检测法在急性髓系白血病中检测突变型NPM1可测量残留病的优势。

Blood Adv. 2025 Mar 11;9(5):1069-1077. doi: 10.1182/bloodadvances.2024014490.

本文引用的文献

DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant.DNA 测序检测造血细胞移植前急性髓系白血病成人患者的残留疾病。

JAMA. 2023 Mar 7;329(9):745-755. doi: 10.1001/jama.2023.1363.

Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission.在首次缓解期和第二次缓解期接受异基因干细胞移植的 AML 患者中，MRD 状态的影响。

Blood Adv. 2022 Aug 9;6(15):4570-4580. doi: 10.1182/bloodadvances.2022007168.

Outcomes of Older Patients with Mutated and -ITD Negative Acute Myeloid Leukemia Receiving Allogeneic Transplantation.接受异基因移植的伴有突变且FLT3-ITD阴性的老年急性髓系白血病患者的预后

Hemasphere. 2020 Jan 3;4(1):e326. doi: 10.1097/HS9.0000000000000326. eCollection 2020 Feb.

Use of Minimal Residual Disease in Acute Myeloid Leukemia Therapy.微小残留病在急性髓系白血病治疗中的应用。

Curr Treat Options Oncol. 2020 Jan 30;21(1):8. doi: 10.1007/s11864-019-0695-5.

Molecular MRD status and outcome after transplantation in NPM1-mutated AML.NPM1 突变型 AML 患者移植后的分子 MRD 状态与预后

Blood. 2020 Feb 27;135(9):680-688. doi: 10.1182/blood.2019002959.

Favorable outcomes for allogeneic hematopoietic cell transplantation in elderly patients with NPM1-mutated and FLT3-ITD-negative acute myeloid leukemia.NPM1 突变且 FLT3-ITD 阴性的老年急性髓系白血病患者接受异基因造血细胞移植的良好结局

Bone Marrow Transplant. 2020 Feb;55(2):473-475. doi: 10.1038/s41409-019-0553-x. Epub 2019 May 14.

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.阿扎胞苷指导下的治疗以预防骨髓增生异常综合征和急性髓系白血病患者血液学复发（RELAZA2）：一项开放标签、多中心、2 期试验。

Lancet Oncol. 2018 Dec;19(12):1668-1679. doi: 10.1016/S1470-2045(18)30580-1. Epub 2018 Nov 12.

Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.基于数字液滴 PCR 的移植前 NPM1 突变负担绝对定量可预测急性髓系白血病患者的复发。

Ann Hematol. 2018 Oct;97(10):1757-1765. doi: 10.1007/s00277-018-3373-y. Epub 2018 May 22.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.急性髓系白血病中的微小残留病：来自欧洲白血病网微小残留病工作组的共识文件。

Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12.

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.诱导后微小残留病预测 NPM1 突变的急性髓系白血病患者异基因造血干细胞移植的疗效和获益：法国急性白血病协会研究组研究。

J Clin Oncol. 2017 Jan 10;35(2):185-193. doi: 10.1200/JCO.2016.67.1875. Epub 2016 Nov 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Quantifying MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献